19:33 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies suggest promoting CTNNB1 citrullination or PAD2 expression could help treat colorectal cancer. Screening of approved drugs in HEK cell-based assays of CTNNB1 signaling and cell line-based citrullination and...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

NT-300: Phase III started

Romark began a double-blind, placebo-controlled, international Phase III trial to compare twice-daily 600 mg NT-300 alone or in combination with twice-daily 75 mg oral Tamiflu oseltamivir for 5 days vs. Tamiflu alone or placebo...
08:00 , Nov 8, 2012 |  BC Innovations  |  Tools & Techniques

MuSIC by design

A Harvard Medical School and Tsinghua University team has developed a technology, dubbed MuSIC, that identifies synergistic drug pairs.1 The group showed proof of concept by finding new combinations of therapeutics for HIV, but weeding...
07:00 , Oct 25, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Multiplex screening for interacting compounds (MuSIC) to help identify drug combinations to treat HIV/AIDS MuSIC could be used...
07:00 , Aug 25, 2011 |  BC Innovations  |  Targets & Mechanisms

More than one way to stop HCV

A French team led byEpixis S.A. has developed an HCVvaccine that triggers both a T cell response and broadly neutralizing antibodies in macaques.1 Because of the ability to elicit both types of immune responses, the...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Pilot trial data

An open-label pilot trial in 5 liver transplant patients showed that oral Alinia reduced HCV viral load in all patients during the first 72 hours post-transplant. However, HCV RNA levels were similar to pre-transplant levels...
07:00 , Nov 1, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Phase II start

Next half, Intercell AG (VSE:ICLL; OTCQX:INRLY, Vienna, Austria) and Romark will begin a European Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's nitazoxanide with or...
07:00 , Nov 1, 2010 |  BC Week In Review  |  Clinical News

Hepatitis C vaccine: Phase II start

Next half, Intercell and Romark Laboratories L.C. (Tampa, Fla.) will begin a European Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's nitazoxanide with or without ...
07:00 , May 3, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Phase II data

Chugai, a subsidiary of Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), has exclusive rights to develop and commercialize Alinia in Japan under a 2009 deal (see BioCentury, Feb. 23, 2009). Alinia for oral suspension and Alinia...
08:00 , Feb 8, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Phase II started

Romark began a double-blind, placebo-controlled, U.S. Phase II trial (RM01-2027) in 440 patients to evaluate 500 mg oral Alinia twice daily for 5 days. Chugai, a subsidiary of Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), has...